Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Chemical and Biological Engineering, University at Buffalo, State University of New York. Buffalo, New York, 14260, USA.
Biomater Sci. 2021 Sep 28;9(19):6381-6390. doi: 10.1039/d1bm00971k.
Malignant pleural effusion (MPE) and malignant ascites (MA), which are common but serious conditions caused by malignancies, are related to poor quality of life and high mortality. Current treatments, including therapeutic thoracentesis and indwelling pleural catheters or paracentesis and catheter drainage, are largely palliative. An effective treatment is urgently needed. MPE and MA are excellent candidates for intratumoural injections that have direct contact with tumour cells and kill tumour cells more effectively and efficiently with fewer side effects, and the fluid environment of MPE and MA can provide a homogeneous area for drug distribution. The immunosuppressive environments within the pleural and peritoneal cavities suggest the feasibility of local immunotherapy. In this review, we introduce the current management of MPE and MA, discuss the latest advances and challenges in utilizing local biomaterial-assisted antitumour therapies for the treatment of MPE and MA, and discuss further opportunities in this field.
恶性胸腔积液（MPE）和恶性腹水（MA）是由恶性肿瘤引起的常见但严重的病症，与生活质量差和死亡率高有关。目前的治疗方法，包括治疗性胸腔穿刺术和留置胸腔导管或腹腔穿刺术和导管引流术，主要是姑息性的。迫切需要有效的治疗方法。MPE 和 MA 是肿瘤内注射的理想候选者，因为肿瘤内注射可直接接触肿瘤细胞，并且以更少的副作用更有效地杀死肿瘤细胞，MPE 和 MA 的液体环境可为药物分布提供均匀区域。胸膜和腹腔内的免疫抑制环境表明局部免疫疗法的可行性。在这篇综述中，我们介绍了 MPE 和 MA 的当前管理方法，讨论了利用局部生物材料辅助抗肿瘤疗法治疗 MPE 和 MA 的最新进展和挑战，并讨论了该领域的进一步机会。
